Adverse effects of RBC transfusions: A unifying hypothesis

红细胞输注的不良反应：统一假设

• 批准号: 8818172
• 负责人: John D Roback
• 金额: $ 87.15万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-17 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8818172
• 关键词: Address; Adverse effects; Affect; Allogenic; Animals; Backcrossings; Biological Markers; Biology; Blood; Blood Banks; Blood Screening; Blood Transfusion; Blood Vessels; Blood donor; Breeding; Canis familiaris; Cell Survival; Cell physiology; Characteristics; Chromosomes, Human, Pair 1; Clinical; Clinical Research; Complex; Data; Defect; Development; Eicosanoids; Enzymes; Erythrocyte Transfusion; Erythrocytes; Etiology; Event; Funding; Generations; Genetic; Genetic Determinism; Genetic Markers; Genotype; Goals; Grant; Hospitals; Hour; Human; In Vitro; Investigation; Knowledge; Lead; Lesion; Link; Longevity; Measures; Mediating; Membrane; Metabolic; Metabolic Marker; Metabolic Pathway; Metabolism; Methodology; Methods; Modeling; Modification; Morbidity - disease rate; Mus; Outcome; Patients; Pattern; Phenotype; Physiological; Poison; Prospective Studies; Quantitative Trait Loci; Recovery; Regulation; Research; Research Personnel; Safety; Sampling; Science; Source; Techniques; Testing; Therapeutic procedure; Time; Transfusion; Validation; Vascular blood supply; Vasodilation; Work; aged; base; congenic breeding; experience; functional disability; genetic element; genetic pedigree; genome wide association study; improved; in vivo; interest; irradiation; metabolomics; mortality; mouse model; novel; prevent; public health relevance; repository; research study; screening; tool

DESCRIPTION (provided by applicant): Transfusion of red blood cells (RBCs), the most common therapeutic procedure performed in US hospitals, is usually effective at preventing morbidity and mortality in anemic patients. However, recent studies indicate that some RBC units have functional defects that impair their efficacy and may actually cause harm to transfused patients. These defects, which appear to increase the longer RBC units are stored prior to transfusion, have been called "RBC storage lesions". Transfusion of RBC units with storage lesions may adversely affect thousands of patients annually, but at present we have no accurate methods to identify such units. During the previous funding period for this R01 grant, we observed unexpected donor-to-donor variability in RBC metabolism during blood bank storage. Based on these data, we propose to identify specific metabolic (human RBCs) and genetic (murine RBCs) biomarkers that not only reflect the underlying differences in RBC function due to storage time and/or donor factors, but also can be used clinically to predict which RBC units may cause adverse post-transfusion events, allowing them to be removed from the blood supply before transfusion. To provide the most powerful approach to achieve this goal, we propose an integrated research effort that combines (1) the relevancy of donor/recipient-based human RBC transfusion investigations, with (2) the mechanistic power of mouse models. The human studies will utilize methodologies we have developed to identify metabolic biomarkers that predict RBC function, post-transfusion RBC survival, and vascular effects. The advantages of mouse studies include finely characterized genetics, rapid breeding times, ease of generating complex pedigrees, and the power of phenotype-genotype analysis. These advantages will be exploited by performing GWAS to identify genetic markers for mouse RBC storage phenotypes, and then selectively backcrossing to establish causality between selected genetic elements and phenotypes of interest. The proposed coordinated investigations allow each model to be used for its unique strengths, while compensating for intrinsic weaknesses, and thus provides efficient cross- validation of selected biomarkers. These studies will extend work started during the previous funding period, and will lead to the validation of RBC biomarkers that we believe will identify RBC units most likely to cause adverse recipient effects, allowing them to be sequestered prior to transfusion.

描述（由申请人提供）：红细胞（RBC）输注是美国医院最常见的治疗程序，通常可有效预防贫血患者的发病率和死亡率。然而，最近的研究表明，一些红细胞单位有功能缺陷，损害其功效，实际上可能会对输血患者造成伤害。这些缺陷似乎增加了输血前RBC单位储存的时间，被称为“RBC储存病变”。输注储存损伤的红细胞单位每年可能会对成千上万的患者产生不利影响，但目前我们还没有准确的方法来识别这些单位。在此R 01赠款的前一个资助期间，我们观察到血库储存期间RBC代谢的意外供体间变异性。基于这些数据，我们建议确定特定的代谢（人红细胞）和遗传（鼠红细胞）生物标志物，这些生物标志物不仅反映了由于储存时间和/或供体因素导致的红细胞功能的潜在差异，而且还可以在临床上用于预测哪些红细胞单位可能导致不良输血后事件，使其在输血前从血液供应中去除。为了提供实现这一目标的最有力的方法，我们提出了一个综合的研究工作，结合（1）供体/受试者为基础的人红细胞输注研究的相关性，（2）小鼠模型的机械力量。人体研究将利用我们开发的方法来鉴定预测RBC功能、输血后RBC存活和血管效应的代谢生物标志物。小鼠研究的优势包括精细表征的遗传学，快速繁殖时间，容易产生复杂的谱系，以及表型-基因型分析的力量。这些优势将通过进行GWAS来利用，以鉴定小鼠RBC储存表型的遗传标记，然后选择性回交以建立所选遗传元件和感兴趣的表型之间的因果关系。所提出的协调研究允许每个模型用于其独特的优势，同时补偿固有的弱点，从而提供所选生物标志物的有效交叉验证。这些研究将延长在上一个资助期开始的工作，并将导致RBC生物标志物的验证，我们相信这些生物标志物将识别最有可能引起受体不良反应的RBC单位，使它们在输血前被隔离。